Genmab — Marts 2016
-
...After much discussion, we agree to start daratumumab. He has had an excellent response, one of the 30 percent of patients who usually respond to this drug, including bone marrow recovery that may allow him to explore other options later on, a true success story. http://www.mywcms.org/news-and-events/newsroom/multiple-myeloma-new-drugs-offer-hope-to-patients
-
så er det ud med hæfte pistolen solsen http://www.investtech.dk/main/market.php?CountryID=45&p=staticPage&fn=newsletter
-
God morgen og velkommen hjem fra eventuel påskeferie til alle.
-
I denne uge er der mulighed for anbefaling om godkendelse af Darzalex i Europa
-
Torsdag?
-
Eller fredag
-
Men jeg har kunnet finde agendaen for denne uges møde. Første betingelse er at det er på agendaen
-
Ikke kunnet finde
-
Ok.
-
Fra Nordea "Vi forventer kursstigninger i Genmab (+1,6%) efter sidste uges gode nyheder og
udsigten til flere forude. Næste potentielle kursdriver er en positiv anbefaling fra
de europæiske sundhedsmyndigheder om at godkende Darzalex i Europa. Det kan
ske allerede i denne uge. Derefter forventes de næste vigtige potentielle kursdrivere
at være foreløbige fase 3-data med lægemidlet i kombinationsbehandlinger med
de mest benyttede knoglemarvskræftmidler. -
Genmab positivt omtalt af Michael Voss i dagens udgave af millionærklubben
-
Følger vi ikke bare det røde marked?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind